Finally, since MARCKS inhibition leads to PTEN upregulation in IBC cells and given the opposite prognostic value of both proteins in IBC, we searched for an eventual prognostic complementarity between MARCKS and PTEN protein: we found that the group “MARCKS-negative/PTEN-positive” displayed longer 5-year MFS (73%) than the remaining group “no MARCKS-negative/PTEN-positive” (33% 5-year MFS). The gene discussed is PTEN; the disease is inflammatory breast carcinoma.